Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Liver Transplant; Complications Clear all

Conditions: Liver Transplant
Interventions: treprostinil sodium, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: End-stage Kidney Disease
Interventions: Inform Me: web-based education tool; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Kidney Disease, Liver Disease, Pancreas Disease
Interventions: RIPC by Inflation of Pneumatic Tourniquet; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months; Drug
Lead sponsor: Camille N. Kotton, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Liver Transplantation
Interventions: Transplant with normothermic machine perfused (NMP) donor liver; Device
Lead sponsor: OrganOx Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Maywood, Illinois + 7 more

Conditions: Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions: Glecaprevir and Pibrentasvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatorenal Syndrome
Interventions: Terlipressin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Liver Failure
Interventions: Vasopressin, Normal saline placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions: PeLTQL delivery via electronic means; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Oakland, California • Atlanta, Georgia • New York, New York + 2 more

Conditions: Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection, Liver Diseases, Hepatitis, Alcoholic, Alcohol-Induced Disorders
Interventions: liver transplant; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cirrhosis, Liver, Sarcopenia
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Liver Transplant
Interventions: MiMedx AmnioFix; Biological
Lead sponsor: Jaekeun Kim; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: End Stage Renal Disease, Chronic Hepatitis c
Interventions: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 34 Years to 44 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End Stage Renal Disease, End Stage Liver Disease
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Not listed
Enrollment: 13,767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Complication of Transplanted Liver
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
Interventions: Renal replacement therapy; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Dysfunction, Rejection, Transplant, Transplantation, Liver
Interventions: Thymoglobulin, Corticosteroid, Tacrolimus, Mycophenolate Mofetil; Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Kidney Failure, Kidney Diseases, Hepatitis C
Interventions: glecaprevir/pibrentasvir tablets; Drug
Lead sponsor: Raymond T. Chung, MD; Other
Eligibility: 30 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions: tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 40
States / cities: Duarte, California • La Jolla, California • Loma Linda, California + 28 more

Conditions: End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
Interventions: TAP, TAU; Behavioral · Other
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 3
States / cities: New York, New York • Richmond, Virginia

Conditions: Obesity, Cardiovascular Disease, Type 2 Diabetes, Hypertension, Complication of Transplant
Interventions: Sleeve Gastrectomy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Disease, Liver Transplantation
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sinusoidal Obstruction Syndrome, Complications of Bone Marrow Transplant
Interventions: shear wave ultrasound elastography; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

Optimizing Kidney Transplant Informed Consent

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

OrganOx Metra® New Enrollment PAS

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Starzl Network Patient Reported Outcomes

Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

Body Composition Changes After TIPS and Associated Clinical Outcomes

Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Transplant Patient Registry of Liver, Kidney and/or Pancreas

Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers

Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Transplant and Addiction Project (TAP) - 1

Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation

Evaluation of Kidney Disease in Liver Transplant Recipients

Using Ultrasound Elastography to Predict Development of SOS